Chanelle Group has launched a new brand and will now be called Chanelle Pharma. The new brand reflects the company’s success and continued growth in the human and animal healthcare sectors and will unify Chanelle’s existing entities including Chanelle Medical, Chanelle Pharmaceuticals Manufacturing, Chanelle Veterinary, Chanelle Animal Health UK and Chanelle Vet UK.
A new website www.chanellepharma.com has also been launched which will support the company’s entry into new markets – the company expects to enter the lucrative US market within the next 18 months. Significant investment in new manufacturing facilities which are being designed and built to FDA quality standards is paving the way for Chanelle Pharma’s expansion. A leading pharma company with a heritage of innovation for over 35 years, Chanelle Pharma currently exports to 96 countries and supplies 10 of the top 12 human generic multinational companies in the world and 10 of the top 12 animal health multinational companies globally.
Michael Burke, Owner, Founder and CEO of Chanelle said; “Chanelle Pharma is a modern and progressive brand for a modern and progressive company. We are competing in global markets, delivering high quality, competitively priced pharmaceuticals and exceeding our customers’ expectations at all times. Our purpose is to provide affordable medicines that extend and improve the lives of people and animals and we have ambitions to become the number 1 generic pharma company in the world. This new brand is part of our €86 million investment programme which is repositioning the company to achieve that ambition. Our entry into the US market will be very significant and is critical to achieving our global growth plans”.
Mr Burke added, “We have retained our distinctive ‘Sea Horse’ logo, which reflects the heritage and ethos of our company. The Sea Horse is unique and in Chanelle we have also set ourselves apart from our competitors with our emphasis on research and development, our continuous pursuit of excellence and the very close relationship we have with our clients and distributors”.
Chanelle Pharma provides a spectrum of services to its customers including research and product development, registration and production of generic pharmaceuticals for both Human and Animal Health Pharmaceuticals. Chanelle has over 2500 animal health licenses and over 2020 product licences for human health products worldwide. It holds the largest number of registered animal health licenses of any company in the EU. It has an enviable reputation for innovation in delivering new generics to market.
In addition to its manufacturing and R&D headquarters in Ireland, Chanelle Pharma also has sales offices in the UK and Mumbai in India and a research and development laboratory in Amman, Jordan.
